Trajectories of Depressive Symptoms Among Patients Undergoing Chemotherapy for Breast, Gastrointestinal, Gynecological, or Lung Cancer
- PMID: 39106444
- DOI: 10.1097/NCC.0000000000001380
Trajectories of Depressive Symptoms Among Patients Undergoing Chemotherapy for Breast, Gastrointestinal, Gynecological, or Lung Cancer
Abstract
Background: Individuals who undergo chemotherapy for cancer are at elevated risk of developing depressive symptoms, yet substantial interindividual variation exists in trajectories of these symptoms.
Objective: To examine interindividual variations in trajectories of depressive symptoms during 2 cycles of chemotherapy and to evaluate associations between demographic and clinical characteristics, symptom severity scores, psychological adjustment characteristics (eg, stress and coping), and initial levels and trajectories of depressive symptoms.
Methods: Patients (n = 1323) diagnosed with breast, gynecologic, lung, or gastrointestinal cancer completed the Center for Epidemiological Studies-Depression Scale 6 times, over 2 cycles of chemotherapy. At enrollment, patients provided demographic information and completed a broad range of symptom, stress, and coping measures. Hierarchical linear modeling was used to identify characteristics associated with initial levels and trajectories of depressive symptoms.
Results: Interindividual differences in initial levels of depressive symptoms were associated with marital status, functional status, level of comorbidity, chemotherapy toxicity, sleep disturbance, morning fatigue, cognitive function, global and cancer-related stress, and coping characteristics (ie, sense of coherence, venting, behavioral disengagement, and self-blame). Interindividual differences in depression trajectories were associated with education, cancer type, chemotherapy toxicity, sleep disturbance, evening energy, evening fatigue, cognitive function, global and cancer-related stress, and self-blame.
Conclusions: We present new findings concerning the trajectories and predictors of depressive symptoms during chemotherapy.
Implications for practice: Modifiable risk factors (eg, stress and coping) are important targets for intervening to address depressive symptoms in oncology patients.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Similar articles
-
Anxiety trajectories: An observational study of women undergoing chemotherapy for breast or gynecological cancer.Eur J Oncol Nurs. 2022 Dec;61:102227. doi: 10.1016/j.ejon.2022.102227. Epub 2022 Oct 13. Eur J Oncol Nurs. 2022. PMID: 36332456
-
Trajectories of Evening Fatigue in Oncology Outpatients Receiving Chemotherapy.J Pain Symptom Manage. 2015 Aug;50(2):163-75. doi: 10.1016/j.jpainsymman.2015.02.015. Epub 2015 Mar 28. J Pain Symptom Manage. 2015. PMID: 25828560 Free PMC article.
-
Risk factors for worse anxiety trajectories among patients undergoing cancer chemotherapy.Support Care Cancer. 2022 Dec 15;31(1):32. doi: 10.1007/s00520-022-07481-w. Support Care Cancer. 2022. PMID: 36517706
-
Predictors and Trajectories of Morning Fatigue Are Distinct From Evening Fatigue.J Pain Symptom Manage. 2015 Aug;50(2):176-89. doi: 10.1016/j.jpainsymman.2015.02.016. Epub 2015 Mar 28. J Pain Symptom Manage. 2015. PMID: 25828559 Free PMC article.
-
Symptom trajectories in patients with breast cancer: An integrative review.Int J Nurs Sci. 2021 Dec 21;9(1):120-128. doi: 10.1016/j.ijnss.2021.12.011. eCollection 2022 Jan. Int J Nurs Sci. 2021. PMID: 35079613 Free PMC article. Review.
References
-
- Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet. 2011;12(2):160–174.
-
- Krebber AMH, Buffart LM, Kleijn G, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23(2):121–130.
-
- Wen S, Xiao H, Yang Y. The risk factors for depression in cancer patients undergoing chemotherapy: a systematic review. Support Care Cancer. 2019;27(1):57–67.
-
- Ibrahim EY, Domenicano I, Nyhan K, et al. Cognitive effects and depression associated with taxane-based chemotherapy in breast cancer survivors: a meta-analysis. Front Oncol. 2021;11:642382.
-
- de Souza BF, de Moraes JA, Inocenti A, dos Santos MA, Silva AE, Miasso AI. Women with breast cancer taking chemotherapy: depression symptoms and treatment adherence. Rev Lat Am Enfermagem. 2014;22(5):866–873.
LinkOut - more resources
Full Text Sources
Research Materials